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Background: Accumulating evidence indicates that mitochondrial energy failure is
involved in the progressive axonal degeneration in multiple sclerosis (MS). In patients with
MS, it has been shown that both levels of N-acetylaspartate (NAA), which is a marker
of axonal mitochondrial energy, and cerebral blood flow (CBF) are reduced in cerebral
normal appearing white matter (NAWM). The latter is likely due to the vasoconstrictive
action of endothelin-1 (ET-1) produced by reactive astrocytes, which is triggered by
local proinflammatory cytokines. A preliminary study in patients with MS showed that
CBF could be restored to normal values after a single dose of 62.5mg of the ET-1
antagonist bosentan.
Objective: To investigate whether restoring CBF in patients with relapsing remitting MS
(RRMS) increases levels of NAA in cerebral NAWM and improves clinical symptoms.
Methods: 27 RRMS patients were included in a 4 weeks proof-of-concept, randomized,
double-blind placebo-controlled trial (ROCHIMS) to investigate whether bosentan
62.5mg twice daily could increase the NAA/creatine (NAA/Cr) ratio in NAWM of the
centrum semiovale. Magnetic resonance imaging (MRI) assessing CBF and NAA/Cr, and
clinical evaluations were performed at baseline and at end of study. Separately from
the clinical trial, 10 healthy controls underwent the same baseline multimodal brain MRI
protocol as the MS patients.
Results: Eleven patients in the bosentan arm and thirteen patients in the placebo arm
completed the study. Bosentan did not increase CBF. However, we found that CBF in
the patients was not different from that of the healthy controls. There were no effects on
NAA levels and clinical symptoms.
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Conclusions: Our study showed that CBF in RRMS patients is not always decreased
and that bosentan has no effect when CBF values are within the normal range. We
hypothesize that in our patients there was no significant astrocytic production of ET-1
because they had a mild disease course, with minimal local inflammatory activity. Future
studies with bosentan in MS should focus on patients with elevated ET-1 levels in
cerebrospinal fluid or blood.
Keywords: multiple sclerosis, cerebral blood flow, endothelin-1, N-acetylaspartate, bosentan, normal appearing
white matter
INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory and
neurodegenerative disorder of the central nervous system
(CNS). The disease pathology is characterized by the occurrence
of focal inflammatory demyelinating lesions responsible for
relapses, and a progressive axonal degeneration responsible for a
more slowly decline of neurologic functions (1). Inflammatory
immune responses play an important role in the pathogenesis of
the focal lesions. However, less is known about the mechanisms
underlying progressive axonal degeneration, which for most
MS patients seems to be the primary determinant of long-term
disability (2).
There is increasing evidence that mitochondrial energy failure
and oxidative stress are involved in the progressive axonal
degeneration of MS (3, 4). In cerebral white matter, the level
of N-acetylaspartate (NAA), an amino acid synthesized by
mitochondria in neurons, is considered a marker of both axonal
mitochondrial activity and axonal integrity (5). 1H-magnetic
resonance spectroscopy (1H- MRS) studies of cerebral normal-
appearing white matter (NAWM) in patients with MS found
reduced NAA levels, as compared to control subjects (1, 6). In
addition, a number of studies found that cerebral blood flow
(CBF) is impaired in NAWMof patients with relapsing-remitting
MS (RRMS), primary progressive MS and also in clinically
isolated syndromes suggestive for MS (CIS-MS) suggesting that
this is independent of the disease course of MS and can
already be present in early phases of the disease (3, 7–12). In
animal models, chronically induced cerebral hypoperfusion leads
to mitochondrial energy failure, oxidative stress, and axonal
degeneration (13). There are several lines of evidence that ATP
synthesis and NAA synthesis are coupled, and a number of
experiments have shown a decrease in NAA levels when brain
energy metabolism is disrupted (5). Thus, in patients with
MS, there might be a link between reduced CBF and axonal
mitochondrial energy failure (5).
An increased production of the potent vasoconstrictive agent
endothelin-1 (ET-1) by reactive astrocytes in focal demyelinated
lesions appears to play an important role in reducing CBF in
patients withMS (3). ETA receptor activation on vascular smooth
muscle cells by ET-1 induces a dose-dependent vasoconstriction
of human cerebral arteries, which can be antagonized by the ET-
1 receptor antagonist bosentan (14). D’Haeseleer et al. found that
the administration of a single 62.5mg dose of bosentan in MS
patients restored CBF to levels similar to healthy controls (3). As
an extension of this study, we performed the ROCHIMS (Role
of Cerebral Hypoperfusion in Multiple Sclerosis) trial, which
was a non-commercial proof-of-concept, placebo-controlled
double-blind, randomized trial investigating whether in RRMS
patients a more prolonged treatment with 62.5mg bosentan
twice daily during ±28 days results in a sustained restoration
of CBF, and whether this enhances NAA levels in NAWM,
reflecting an improvement of axonal mitochondrial metabolism.
Furthermore, we wanted to explore if the restoration of CBF has
an influence on clinical symptoms.
However, the results of our study were negative, but no less
interesting as it further contributes to a better understanding of
the role of CBF in the pathophysiology of MS.
METHODS
Subjects and Procedures
The ROCHIMS trial was conducted at the Universitair
Ziekenhuis (UZ) Brussel, Belgium, between October 2017 and
March 2019. The protocol of the study has been described
in detail in TRIALS (15). The study was registered by the
European Union Drug Regulating Authorities (Eudra-CT 2017-
001253-13) and was approved at national level by the Federaal
Agentschap Voor Geneesmiddelen en Gezondheidsproducten
(FAGG, Belgium) as well as by the ethics committee of the UZ
Brussel. All patients gave written informed consent.
Patients with a diagnosis of RRMS, according to the 2010
revised McDonald Criteria (16), aged above 18 years and with an
ExpandedDisability Status Score (EDSS) less or equal than 4 were
enrolled in the study. The exclusion criteria were an MS relapse
within the last 3 months before inclusion, pregnancy or lactation,
major liver dysfunction, use of cyclosporine A or glibenclamide,
or allergy to bosentan. For sexually active female patients with
reproductive potential, use of reliable means of contraception
was required.
Randomization of the patients was performed on day 0 with
“research randomizer” (https://randomizer.org), using 5 sets of
6 numbers in order to achieve an equal distribution between
the active product (bosentan) and placebo. Bosentan tablets of
62.5mg were provided by Actelion Pharmaceuticals Belgium NV
(Mechelen, Belgium) and identical-looking placebo tablets were
produced by the Hospital Pharmacy of the UZ Brussel.
At baseline, all patients underwent multimodal brain MRI
consisting of a high-resolution anatomical scan, 3D fluid-
attenuated inversion recovery, arterial spin labeling (ASL) and
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1HMRS on a 3 Tesla machine (GE, MR 750W Discovery). Total
scanning time was about 30min. The regions of interest for CBF
and NAA/creatine (NAA/Cr) quantification were the left and
right centrum semiovale NAWM. The final results represent the
average of the measurements in left and right centrum semiovale.
All further technical details, including the software used for
analysis of the ASL data and spectroscopic data are described in
TRIALS (15).
All patients were assessed for a number of clinical parameters
(a) fatigue, scored by the Fatigue Severity Scale (FSS), Modified
Fatigue Impact Scale-5-item version (MFIS-5) and Fatigue Scale
forMotor and Cognitive functions (FSMC), (b) depression by the
Beck Depression Inventory-II, (c) a Brief International Cognitive
Assessment for Multiple Sclerosis (BICAMS) consisting of
Symbol Digit Modality Test (SDMT), California Verbal Learning
Test (CVLT-II), and Brief Visuospatial Memory Test-Revised
(BVMT-R), and (d) motor function of lower limbs by the Timed
25 Foot Walk Test (T25FWT) and of the upper limbs by the 9-
Hole Peg Test (9HPT). All these tests are described in detail in
TRIALS (15).
The daily intake of two tablets of study medication (one tablet
at 8:00 a.m. and one tablet at 8:00 p.m.) started on day 1 and
continued until day 28 (±2 days).
All evaluations described above were repeated at end of study.
On the evaluation days, participants were asked to refrain from
alcohol or caffeine, as well as not to smoke. Two weeks after
ending the trial, participants were called at home to see if any
side effects had occurred during the trial.
Not part of the ROCHIMS trial, 10 healthy controls
underwent the same baseline multimodal brain MRI protocol
as the patients with MS. This study was also approved by the
ethics committee of the UZ Brussel. All controls gave written
informed consent.
Outcomes
The primary outcome of the ROCHIMS study was the change
in NAA/Cr ratio in centrum semiovale NAWM, reflecting
changes in axonal mitochondrial metabolism. Secondary
clinical endpoints were the differences in change in fatigue,
cognition, depression, and motor function, between the two
treatment groups.
Statistical Analyses
Sample size calculation was based on the study of Steen
et al. NAA/Cr in centrum semiovale NAWM was found
to be 10% lower in MS patients compared to healthy
controls (6). It was estimated that 12 patients in each group
would be needed to detect a 10% increase in NAA/Cr in
centrum semiovale NAWM in the bosentan group compared
to the placebo group (alpha value = 0.05, power 90%).
Taking into account asymptomatic efficiency loss and potential
dropouts, inclusion of 15 patients in each group were
deemed sufficient.
The Wilcoxon signed-rank test for paired samples compared
differences of parameters within one treatment group, and
the Mann–Whitney U-test to compared differences between
FIGURE 1 | Consort Diagram of the ROCHIMS trial.
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TABLE 1 | Demographics and baseline values of the RRMS patients who
completed the study.
Bosentan (n = 11) Placebo (n = 13)
Sex (female) 6 (54 %) 10 (77%)
AGE* (YEARS)
Mean (SD) 44 (8) 38 (6)
Median (Q1, Q3) 45 (38, 53) 37 (34, 42)
DISEASE DURATION (YEARS)
Mean (SD) 6.9 (5.1) 5.8 (4.7)
Median (Q1, Q3) 5 (4, 14) 3 (2, 9)
EDSS
Mean (SD) 1.55 (1.17) 1.19 (1.15)
Median (Q1, Q3) 2 (0, 2) 1.5 (0, 2)
DISEASE-MODIFYING TREATMENT
Yes 9 (81.82%) 12 (92.31%)
Natalizumab 2 4
Dimethyl fumarate 2 2
Interferon 1 3





Mean (SD) 2 (0.19) 2.04 (0.19)
Median (Q1, Q3) 1.98 (1.87, 2.11) 1.96 (1.89, 2.27)
CBF (ml/100 g/min)
Mean (SD) 26.54 (3.81) 26.04 (2.70)
Median (Q1, Q3) 26.78 (23.21, 28.37) 26.27 (24.26, 28.32)
FSS
Mean (SD) 39.18 (12.43) 34.62 (8.80)
Median (Q1, Q3) 45 (30, 58) 34 (27, 40.5)
MFIS
Mean (SD) 9.73 (4.57) 10.15 (2.23)
Median (Q1,Q3) 11 (4, 16) 10 (8.5, 12)
FSMC
Mean (SD) 54.40 (20.75) 56.23 (14.32)
Median (Q1, Q3) 60 (34.75, 67.50) 53 (44.5, 71)
BDI-II
Mean (SD) 9.91 (7.05) 9.54 (6.65)
Median (Q1, Q3) 9 (4, 16) 9 (5, 13)
SDMT
Mean (SD) 51.27 (11.42) 54.85 (7.16)
Median (Q1,Q3) 51 (45, 57) 56 (48.5, 60.5)
CVLT-II
Mean (SD) 56.55 (11.29) 58.62 (8.60)
Median (Q1, Q3) 61 (46, 67) 62 (52.5, 63)
BVMT-R
Mean (SD) 26.91 (7.30) 30.08 (4.35)
Median (Q1, Q3) 30 (22, 33) 31 (28.5, 32.5)
T25FWT
Mean (SD) 4.66 (0.61) 4.80 (0.66)
Median (Q1, Q3) 4.36 (4.28, 5.08) 4.54 (4.35, 5.32)
9HPT
Mean (SD) 20.33 (4.54) 18.66 (2.02)
Median (Q1, Q3) 19.28 (17.39, 20.57) 17.94 (17.11, 20.14)
EDSS, Expanded Disability Status Score; MSSS, Multiple Sclerosis Severity Score; NAA-
Cr, N-acetylaspartate/creatinine; CBF, Cerebral Blood Flow; FSS, Fatigue Severity Scale;
MFIS, Modified Fatigue Impact Scale; FSMC, Fatigue Scale for Motor and Cognitive
functions; BDI-II, Beck Depression Inventory-II; SDMT, Symbol Digit Modalities Test; CVLT-
II, California Verbal Learning Test-II; BVMT-R, Brief Visuospatial Memory Test-Revised;
T25FWT, Timed 25 Foot Walk Test; 9HPT, 9-Hole Peg Test. *p < 0.05.
the groups. The level for statistical significance was defined
as p < 0.05.
RESULTS
A total number of 27 patients with RRMS were randomly
assigned to either bosentan (n = 13) or placebo (n = 14). The
Consort Diagram is shown in Figure 1.
Two patients in the bosentan group and one patient in the
placebo did not complete the study.
Demographic characteristics and baseline parameters of
the RRMS patients are shown in Table 1. There were no
significant differences between the two treatment groups, except
for age.
For the two treatment groups, there was no significant change
in (mean ± SD) CBF values in centrum semiovale NAWM
between baseline and end of the study in the bosentan group (26.5
± 3.8 vs. 26.9 ± 3.7 ml/100 g/min) and the placebo group (26.0
± 2.7 vs. 26.0 ± 2.4 ml/100 g/min). Individual values are shown
in Figure 2.
No significant change was found in (mean ± SD) NAA/Cr
ratio between baseline and end of the study in the bosentan group
(2.00 ± 0.19 vs. 1.95 ± 0.18) and the placebo group (2.04 ± 0.19
vs. 2.09± 0.17).
For all secondary outcome parameters there were
no differences between the two treatment groups over time.
The treatment was well-tolerated without side effects, with the
exception of one patient in the placebo group who discontinued
because of dizziness.
The mean (±SD) age of the healthy controls (38 ± 12
years) and gender balance (5 females/5 males) were not
significantly different form the RRMS patients. There was no
significant difference in (mean ± SD) CBF values in centrum
semiovale NAWM at baseline between healthy controls (24.75
± 9.13 ml/100 g/min) and the RRMS patients (26.12 ±
3.14 ml/100 g/min). No significant difference was found in
(mean ± SD) NAA/Cr ratio at baseline between the healthy
controls (1.93 ± 0.73) and the RRMS patients (2.02 ± 0.18)
(Figure 3).
DISCUSSION
In this proof-of concept trial, we found no increase in CBF in
NAWM of the centrum semiovale of RRMS patients treated for
28 days with the ET-1 antagonist bosentan. Accordingly, we did
not find an effect on NAA levels in NAWM of the centrum
semiovale and on the clinical parameters. This negative result was
unexpected since D’Haeseleer et al. found that in MS patients,
CBF increased to values similar to those in healthy control
subjects after a single intake of one tablet of 62.5mg bosentan (3).
However, in that study, CBF in the centrum semiovale NAWMof
the MS patients was about 20% lower than that measured in age
and sex matched healthy controls. To the best of our knowledge,
no other studies have investigated the effects of bosentan on CBF
in MS patients.
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FIGURE 2 | Individual CBF values in the centrum semiovale NAWM at baseline and end of study.
FIGURE 3 | CBF values and NAA/Cr ratios in healthy controls and RRMS patients randomized to bosentan or placebo.
In NAWM of the corpus callosum of MS patients, Saindane
et al. found that the decreased CBF did not correlate with
fractional anisotropy, suggesting that reduced perfusion in the
NAWM of MS patients is not just a consequence of axonal
degeneration (17). D’Haeseleer et al. found that ET-1 produced
by reactive astrocytes in MS plaques is likely responsible
for the reduced CBF in MS patients (3). They found that
astrocytes in postmortem samples of cerebral white matter
from individuals without neurological disease did not visually
show ET-1 immunostaining, whereas reactive astrocytes in
demyelinated plaques form patients with secondary progressive
MS were strongly positive for ET-1. This ET-1 production leads
to increased ET-1 levels in cerebrospinal fluid (CSF) and blood
of patients with MS (3, 18–20). However, significance is at
group level, and these studies show that there are also MS
patients who, at the moment of sampling, have no increased
ET-1 levels in CSF or blood. ET-1 levels were significantly
increased in CSF of RRMS patients with an acute clinical
attack in comparison with those in a stable phase (18). Rocha
et al. found no association between plasma ET-1 levels and
peripheral immune markers (20). However, we recently showed
that the pro-inflammatory cytokines IL-1β and TNF-α, which
are present in active inflammatory MS plaques, stimulated ET-1
secretion in cultured human astrocytoma cells (21). All together,
these findings indicate that local inflammatory mechanisms
in MS plaques are likely the trigger for the astrocytic ET-1
production that is responsible for lowering CBF in patients
with MS.
We found that CBF in the centrum semiovale NAWM in
our RRMS population was not different from that of healthy
controls who were investigated with the same cerebral MRI
protocol, software and scanner. After the start of our clinical
trial, a number of studies reported that in MS patients there is
a relationship between disease severity and the degree of cerebral
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hypoperfusion (22, 23). The patients in our trial were only mildly
disabled (low EDSS scores and normal NAA/Cr ratios), and
most were satisfactorily treated with immunomodulatory drugs,
suggesting that their normal CBF values were related to minimal
focal inflammatory activity in their CNS, so that there is no
significant astrocytic production of ET-1. A major limitation
of our study is that we did not measure ET-1 levels in blood
or CSF.
Subarachnoid perivascular micro-application of bosentan
on individual pial arterioles on the cortical surface of
anesthetized cats only had minimal effect on pial arteriolar
caliber. Subarachnoid perivascular micro-application of
ET-1 effected a marked reduction in pial arteriolar caliber,
which could be attenuated either by co-administration of
bosentan or by the intravenous administration of bosentan
(24). The administration of intravenous bosentan in
anesthetized pigs also did not significantly change CBF
measured with positron emission tomography (25). In a rat
model of pneumococcal meningitis, ET-1 levels increased
five-fold in the CSF, and CBF was significantly reduced by
about 50%. CBF was restored to levels similar to controls
after intraperitoneal administration of bosentan (26). All
these data indicate that bosentan only has a significant
effect on the CBF in conditions associated with local ET-1
production causing some degree of vasoconstriction of the
cerebral vasculature.
Astrocytic ET-1 production and decreased CBF may be an
important modifiable aggravating factor for disease progression
inMS patients, but not all, as our study has shown. A recent study
showed that significantly higher CSF levels of ET-1 were found
in MS patients with aggressive optic neuritis (ON) compared
to non-aggressive ON (27). MS patients with decreased CBF
may benefit from therapies blocking astrocytic ET-1 production
or ET-1 antagonists. However, future clinical trials assessing
possible beneficial effects of bosentan in patients with MS
should only include patients with increased blood or CSF levels
of ET-1.
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